{"nctId":"NCT00372593","briefTitle":"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia","startDateStruct":{"date":"2006-08"},"conditions":["Leukemia"],"count":1070,"armGroups":[{"label":"Arm A: Standard Arm - No GMTZ, AML Pts w/out Down Syndrome","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: asparaginase","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: etoposide","Drug: mitoxantrone hydrochloride"]},{"label":"Arm B: Experimental - with GMTZ, AML Pts w/out Down Syndrome","type":"EXPERIMENTAL","interventionNames":["Drug: asparaginase","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: etoposide","Drug: gemtuzumab ozogamicin","Drug: mitoxantrone hydrochloride"]},{"label":"Arm A: Standard Arm - No GMTZ, AML Patients with Down Syndrome","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: asparaginase","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: etoposide","Drug: mitoxantrone hydrochloride"]}],"interventions":[{"name":"asparaginase","otherNames":["E.coli","E.coli L-asparaginase","EC 3.5.2.2","colaspase","L-asnase","Elspar","Kidrolase","Crasnitin","Leunase","NSC 109229"]},{"name":"cytarabine","otherNames":["Cytosine arabinoside","Ara-C","Cytosar","NSC # 63878"]},{"name":"daunorubicin hydrochloride","otherNames":["Daunomycin","rubidomycin","Cerubidine","NSC #82151"]},{"name":"etoposide","otherNames":["VePesid","Etopophos","VP-16","NSC #141540"]},{"name":"gemtuzumab ozogamicin","otherNames":["Mylotarg","GMTZ"]},{"name":"mitoxantrone hydrochloride","otherNames":["Novantrone","CL 232315","DAD","DHAD","Mitozantrone","NSC #301739"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Newly diagnosed acute myeloid leukemia (AML)\n\n  * Meets customary criteria for AML with ≥ 20% bone marrow blasts (by WHO classification)\n\n    * Patients with \\< 20% bone marrow blasts and cytopenia or myelodysplastic syndromes (e.g., chronic myelomonocytic leukemia, refractory anemia (RA), RA with excess blasts, RA with ringed sideroblasts) are eligible provided 1 of the following criteria is met:\n\n      * Karyotypic abnormality characteristic of de novo AML (t\\[8;21\\]\\[q22;q22\\], inv\\[16\\]\\[p13q22\\], t\\[16;16\\]\\[p13;q22\\], or 11q23 abnormalities)\n      * Unequivocal presence of megakaryoblasts (by WHO classification)\n  * Isolated myeloid sarcoma (i.e., myeloblastoma or chloroma) allowed regardless of bone marrow results\n* Infants \\< 1 month of age with progressive disease\\* are eligible NOTE: \\*Infants \\< 1 month of age with AML may be given supportive care until it is clear that the leukemia is not regressing (i.e., the disappearance of peripheral blasts and the normalization of peripheral blood counts)\n* Patients with Down syndrome ≥ 4 years of age are eligible\n* No juvenile myelomonocytic leukemia\n* No Fanconi's anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome\n* No promyelocytic leukemia (M3)\n* No secondary or treatment-related AML\n* Matched family donor criteria (for patients with intermediate-risk or high-risk disease):\n\n  * HLA-A, -B, -C, and beta chain (-DRB1), identical or 1 antigen or allele mismatched by molecular high resolution technique\n  * All available first-degree family members (parents and siblings) must be HLA typed\n  * No syngeneic donors\n* Matched alternative donor criteria (for patients with high-risk disease):\n\n  * HLA-A, -B, -C, and -DRB1, identical or 1 antigen or allele mismatched donor\n  * HLA-A, -B, and -DRB1 4 of 6 antigen matched unrelated cord blood donor\n  * Mismatched family member donor with ≥ 1 haplotype match or 5 of 6 antigen phenotypic match\n\nPATIENT CHARACTERISTICS:\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior chemotherapy, radiation therapy, or any antileukemic therapy\n\n  * Topical or inhalation steroids for other conditions allowed\n  * Intrathecal cytarabine given at diagnosis allowed\n* No other prior treatment for AML\n* No concurrent peripheral blood stem cell transplantation in patients with matched family donor","healthyVolunteers":false,"sex":"ALL","maximumAge":"29 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival at 3 Years","description":"The Kaplan-Meier method will be used to calculate estimates of Event Free Survival (EFS). The log-rank test will be used to compare survival between treatment groups. Analysis of EFS of Down syndrome patients will be performed separately. Monitoring for efficacy of GMTZ with respect to Overall Survival (OS) and EFS will utilize monitoring based on the Lan-DeMets criterion with α-spending function αt\\^2 (truncated at 3 standard deviations) and 2.5% type I error.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"53.1","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival at 3 Years","description":"The Kaplan-Meier method will be used to calculate estimates of OS. Analysis of OS of Down syndrome patients will be performed separately. Monitoring for efficacy of GMTZ with respect to OS and EFS will utilize monitoring based on the Lan-DeMets criterion with α-spending function αt\\^2 (truncated at 3 standard deviations) and 2.5% type I error.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.4","spread":null},{"groupId":"OG001","value":"69.4","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission Induction Rate After 2 Courses of Induction Therapy","description":"Patients without an evaluable bone marrow at the end of Induction I will be excluded from the calculation of remission rate after 2 courses of therapy because their responses are not evaluable. The following patients will be considered to not be in complete remission (CR) after 2 courses of therapy: (1) patients who die during Induction I and II; (2) patients with ≥ 5% blasts or extramedullary disease at the end of Induction II.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.851324","spread":null},{"groupId":"OG001","value":"0.882716","spread":null},{"groupId":"OG002","value":"0.666667","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival (DFS)","description":"Time from end of Intensification I to relapse, death or last contact","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.6","spread":null},{"groupId":"OG001","value":"63.0","spread":null},{"groupId":"OG002","value":"75.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality","description":"Number of participants who died during the first three courses of therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Marrow Recovery","description":"Mean time to ANC recovery - defined as ANC greater than 500/MicroLiter for 3 consecutive days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.56","spread":"6.96"},{"groupId":"OG001","value":"30.56","spread":"6.47"},{"groupId":"OG002","value":"29.17","spread":"2.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.54","spread":"6.69"},{"groupId":"OG001","value":"28.52","spread":"6.25"},{"groupId":"OG002","value":"26.6","spread":"4.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.51","spread":"5.95"},{"groupId":"OG001","value":"28.10","spread":"6.32"},{"groupId":"OG002","value":"24.5","spread":"3.70"}]}]}]},{"type":"SECONDARY","title":"Toxicities, Including Infectious Complications","description":"Number of participants with at least one grade 3 or higher adverse event during therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"482","spread":null},{"groupId":"OG001","value":"477","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":511},"commonTop":["Infections and infestations - Other","Febrile neutropenia","Hypokalemia","Anorexia","Hyperglycemia"]}}}